Response to anti-VEGF-A treatment of endothelial cells in vitro.

Experimental Eye Research
Alessandra PudduMassimo Nicolò

Abstract

This study was conducted to compare the effects of two anti-VEGF-A drugs, Ranibizumab and Aflibercept, on the expression and secretion of VEGFs family members, and on their influence in proliferation and migration of endothelial cells (HECV) in vitro. HECV cells were exposed 24 h (T1), 4 days (T2) and 6 days (T3) to Ranibizumab or Aflibercept at pharmacodynamically relevant concentrations (Ranibizumab: 12.5 μg/ml and 125 μg/ml; Aflibercept: 50 μg/ml and 500 μg/ml). Cell viability and then expression and secretion of VEGF-A, VEGF-B, VEGF-C and PlGF were evaluated respectively by Real Time-PCR and ELISA. Intracellular signaling activated by VEGF-A and VEGF-C was investigated evaluating phosphorylation of VEGFR2. Influence in would healing was evaluated through scratch assay. In general no differences were observed among the tested concentrations of anti-vegf drugs. Ranibizumab and Aflibercept did not affect HECV cell viability in all experimental times. At T1, Ranibizumab decreased mRNA levels of VEGF-A, induced VEGF-C secretion, abrogated phosphorylation of VEGFR2 stimulated by VEGF-A, and impaired ability of HECV cells to repair wound healing. Aflibercept decreased mRNA levels of VEGF-A, -B and PlGF; slightly increased basal le...Continue Reading

References

Sep 23, 2000·Nature·P Carmeliet, R K Jain
Apr 28, 2004·JAMA : the Journal of the American Medical Association·Neil M Bressler
Dec 17, 2004·Pharmacological Reviews·Ann HoebenErnst A De Bruijn
Jan 22, 2005·Current Opinion in Genetics & Development·Peter BalukDonald M McDonald
Jun 27, 2006·Investigative Ophthalmology & Visual Science·Magali Saint-GeniezPatricia A D'Amore
Feb 9, 2007·Journal of Clinical Pharmacy and Therapeutics·I Krämer, H-P Lipp
May 26, 2007·Investigative Ophthalmology & Visual Science·Peter HeiduschkaUNKNOWN Tübingen Bevacizumab Study Group
Nov 15, 2007·Proceedings of the National Academy of Sciences of the United States of America·John S RudgeGeorge D Yancopoulos
Jan 15, 2008·Metabolism: Clinical and Experimental·Giorgio Luciano VivianiPatrizio Odetti
Sep 4, 2008·Cell and Tissue Research·Yongping Crawford, Napoleone Ferrara
Apr 17, 2009·Proceedings of the National Academy of Sciences of the United States of America·Fan ZhangXuri Li
Jul 29, 2009·Nature Reviews. Clinical Oncology·Axel Grothey, Evanthia Galanis
Jan 24, 2013·Therapeutic Advances in Chronic Disease·Matthew Ohr, Peter K Kaiser

❮ Previous
Next ❯

Citations

Jul 26, 2017·British Journal of Cancer·Rajat BhattacharyaLee M Ellis
Feb 6, 2018·Eye·Stefano FogliRomano Danesi
Jun 7, 2016·Journal of Neuroscience Research·Shubhangi PrabhudesaiSimon Geir Møller

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Cell Migration

Cell migration is involved in a variety of physiological and pathological processes such as embryonic development, cancer metastasis, blood vessel formation and remoulding, tissue regeneration, immune surveillance and inflammation. Here is the latest research.

Related Papers

Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie
Heidrun L DeisslerGabriele E Lang
Cellular and Molecular Life Sciences : CMLS
David A Greenberg, Kunlin Jin
Biochemical and Biophysical Research Communications
Margrit HollbornLeon Kohen
© 2022 Meta ULC. All rights reserved